These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 19808982

  • 1. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR, Stribbling SM, Pruijn FB, Syddall SP, Patterson AV, Liyanage HD, Smith E, Botting KJ, Tercel M.
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [Abstract] [Full Text] [Related]

  • 2. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
    Green LK, Syddall SP, Carlin KM, Bell GD, Guise CP, Mowday AM, Hay MP, Smaill JB, Patterson AV, Ackerley DF.
    Mol Cancer; 2013 Jun 10; 12():58. PubMed ID: 23758947
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M, Atwell GJ, Yang S, Stevenson RJ, Botting KJ, Boyd M, Smith E, Anderson RF, Denny WA, Wilson WR, Pruijn FB.
    J Med Chem; 2009 Nov 26; 52(22):7258-72. PubMed ID: 19877646
    [Abstract] [Full Text] [Related]

  • 4. A Novel Depurination Methodology to Assess DNA Alkylation of Chloro-Bis-Seco-Cyclopropylbenzoindoles Allowed for Comparison of Minor-Groove Reactivity.
    Wang S, Chen B, Dragovich P, Pillow T, Staben L, Guo J, Su D, Zhang C, Bobba S, Ma Y, Wang J, Sangaraju D, Wei B, Phillips GL, Khojasteh C, Zhang D.
    Drug Metab Dispos; 2019 May 26; 47(5):547-555. PubMed ID: 30858239
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA.
    J Med Chem; 2003 Dec 04; 46(25):5533-45. PubMed ID: 14640560
    [Abstract] [Full Text] [Related]

  • 6. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
    Radiat Res; 2007 Jun 04; 167(6):625-36. PubMed ID: 17523848
    [Abstract] [Full Text] [Related]

  • 7. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
    Stevenson RJ, Denny WA, Ashoorzadeh A, Pruijn FB, van Leeuwen WF, Tercel M.
    Bioorg Med Chem; 2011 Oct 15; 19(20):5989-98. PubMed ID: 21920763
    [Abstract] [Full Text] [Related]

  • 8. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
    Hong CR, Mehta SY, Liyanage HDS, McManaway SP, Lee HH, Jaiswal JK, Bogle G, Tercel M, Pruijn FB, Wilson WR, Hicks KO.
    Cancer Chemother Pharmacol; 2021 Oct 15; 88(4):673-687. PubMed ID: 34245333
    [Abstract] [Full Text] [Related]

  • 9. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
    Tercel M, Yang S, Atwell GJ, Smith E, Gu Y, Anderson RF, Denny WA, Wilson WR, Pruijn FB.
    Bioorg Med Chem; 2010 Jul 15; 18(14):4997-5006. PubMed ID: 20580559
    [Abstract] [Full Text] [Related]

  • 10. The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins.
    Ashoorzadeh A, Atwell GJ, Pruijn FB, Wilson WR, Tercel M, Denny WA, Stevenson RJ.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4851-60. PubMed ID: 21767954
    [Abstract] [Full Text] [Related]

  • 11. DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145.
    Kiakos K, Sato A, Asao T, McHugh PJ, Lee M, Hartley JA.
    Mol Cancer Ther; 2007 Oct 15; 6(10):2708-18. PubMed ID: 17938264
    [Abstract] [Full Text] [Related]

  • 12. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
    Stevenson RJ, Denny WA, Tercel M, Pruijn FB, Ashoorzadeh A.
    J Med Chem; 2012 Mar 22; 55(6):2780-802. PubMed ID: 22339090
    [Abstract] [Full Text] [Related]

  • 13. Preparation and antitumour properties of the enantiomers of a hypoxia-selective nitro analogue of the duocarmycins.
    Tercel M, Lee HH, Yang S, Liyanage HD, Mehta SY, Boyd PD, Jaiswal JK, Tan KL, Pruijn FB.
    ChemMedChem; 2011 Oct 04; 6(10):1860-71. PubMed ID: 21793220
    [Abstract] [Full Text] [Related]

  • 14. Initial development of a cytotoxic amino-seco-CBI warhead for delivery by prodrug systems.
    Twum EA, Nathubhai A, Wood PJ, Lloyd MD, Thompson AS, Threadgill MD.
    Bioorg Med Chem; 2015 Jul 01; 23(13):3481-9. PubMed ID: 25963825
    [Abstract] [Full Text] [Related]

  • 15. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
    Ahn GO, Botting KJ, Patterson AV, Ware DC, Tercel M, Wilson WR.
    Biochem Pharmacol; 2006 Jun 14; 71(12):1683-94. PubMed ID: 16620789
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.
    J Med Chem; 2007 Mar 22; 50(6):1197-212. PubMed ID: 17326614
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP, Atwell GJ, Wilson WR, Pullen SM, Denny WA.
    J Med Chem; 2003 Jun 05; 46(12):2456-66. PubMed ID: 12773049
    [Abstract] [Full Text] [Related]

  • 18. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW, Jaiswal JK, Hurley DG, Liyanage HD, McManaway SP, Gu Y, Richter S, Wang J, Tercel M, Print CG, Wilson WR, Pruijn FB.
    Biochem Pharmacol; 2014 May 15; 89(2):224-35. PubMed ID: 24632291
    [Abstract] [Full Text] [Related]

  • 19. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.
    Biochem Pharmacol; 2018 Oct 15; 156():265-280. PubMed ID: 30134191
    [Abstract] [Full Text] [Related]

  • 20. N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs.
    Lu GL, Stevenson RJ, Chang JY, Brothers PJ, Ware DC, Wilson WR, Denny WA, Tercel M.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4861-7. PubMed ID: 21775153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.